S&P 500
(0.08%) 5 252.59 points
Dow J
(0.05%) 39 779 points
Nasdaq
(-0.05%) 16 391 points
Oil
(1.67%) $82.71
Gas
(0.58%) $1.728
Gold
(1.07%) $2 236.30
Silver
(0.74%) $24.94
Platinum
(1.38%) $922.25
USD/EUR
(0.26%) $0.926
USD/NOK
(0.64%) $10.84
USD/GBP
(-0.01%) $0.791
USD/RUB
(0.10%) $92.53

Realtime updates for Context Therapeutics Inc. [CNTX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated28 Mar 2024 @ 12:19

3.60% $ 1.440

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 12:19):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers...

Stats
Today's Volume 32 039.00
Average Volume 46 565.00
Market Cap 22.99M
EPS $0 ( 2024-03-27 )
Next earnings date ( $-0.390 ) 2024-05-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.960
ATR14 $0.0210 (1.46%)
Insider Trading
Date Person Action Amount type
2024-03-21 Minai-azary Jennifer Lynn Buy 160 115 Stock Option (right to buy)
2024-03-21 Levit Alex C. Buy 153 515 Stock Option (right to buy)
2024-03-21 Lehr Martin A. Buy 291 402 Stock Option (right to buy)
2023-05-31 Kantoff Philip W. Buy 25 000 Stock Option (right to buy)
2023-05-31 West Linda Buy 25 000 Stock Option (right to buy)
INSIDER POWER
100.00
Last 72 transactions
Buy: 4 162 098 | Sell: 2 098 089

Volume Correlation

Long: -0.11 (neutral)
Short: 0.52 (weak)
Signal:(53.506) Neutral

Context Therapeutics Inc. Correlation

10 Most Positive Correlations
SGH0.957
KOPN0.957
PLAB0.949
ALR0.941
STER0.939
ELTK0.938
MRVL0.935
XBIT0.931
EVLO0.927
CALA0.927
10 Most Negative Correlations
OPTN-0.919
SBNYP-0.909
ASO-0.901
FANH-0.899
ATHN-0.896
PHCF-0.895
CDAK-0.885
PAYS-0.885
MTSI-0.877
AGFS-0.876

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Context Therapeutics Inc. Correlation - Currency/Commodity

The country flag -0.02
( neutral )
The country flag -0.57
( weak negative )
The country flag 0.00
( neutral )
The country flag -0.31
( neutral )
The country flag 0.11
( neutral )
The country flag -0.07
( neutral )

Context Therapeutics Inc. Financials

Annual 2023
Revenue: $0
Gross Profit: $-12 044.00 (0.00 %)
EPS: $-1.500
Q4 2023
Revenue: $0
Gross Profit: $-2 568.00 (0.00 %)
EPS: $-0.420
Q3 2023
Revenue: $0
Gross Profit: $-3 089.00 (0.00 %)
EPS: $-0.370
Q2 2023
Revenue: $0
Gross Profit: $-3 194.00 (0.00 %)
EPS: $-0.310

Financial Reports:

No articles found.

Context Therapeutics Inc.

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators